Overview

Press Releases

See All »

Media Coverage

December 8, 2014

New to the Street Interview with NeoStem

Chairman and CEO Dr. Robin L. Smith and Chief Medical Officer Dr. Douglas Losordo join New to the Street host Ken Evseroff to discuss NeoStem's pipeline of therapeutic products, the recent release of Phase 2 PreSERVE AMI clinical trial initial results, and an upcoming Phase 3 clinical trial investigating the Company's targeted cancer immunotherapy, NBS20, in patients with late-stage metastatic melanoma.


November 17, 2014

Dr. Arshed Quyyum interviewed at American Heart Association Scientific Sessions

Dr. Arshed Quyyum, MD, FACC, Professor of Medicine at Emory University and Lead Principal Investigator of NeoStem’s PreSERVE AMI clinical study, discusses data released from trial at the American Heart Association's Scientific Sessions.


October 13, 2014

NeoStem Acquires Its Way to the Top

Dr. Robin Smith, CEO of NeoStem, discusses how the acquisition of six biotech companies has enabled her to find talent in the emerging industry of cell therapy.


See All »

Upcoming Events

12th International Symposium on Stem Cell Therapy & Cardiovascular Innovations

May 28, 2015 - 11:18 AM CET
Aula Magna. Pabellón Docente. Hospital Universitario Gregorio Marañón, Madrid, Spain

Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell based therapies to prevent and cure heart failure. More than an adventure?


2015 Marcum MicroCap Conference

May 28, 2015 - 11:00 AM ET
Grand Hyatt New York, NY

Presenter: Dr. David J. Mazzo, Chief Executive Officer
Topic: Company Presentation


2015 ASCO Annual Meeting

June 1, 2015 - 1:15 – 4:45 PM CT

Presenter: Dr. Robert O. Dillman, Vice President, Oncology
Poster: Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (INTUS trial)


See All »

Video

See All »

NeoStem - Cell Therapy Development - Media Section